2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
73
Colonic Neoplasms
14
Rectal Neoplasms
13
Neoplasm Metastasis
12
Stomach Neoplasms
8
Pancreatic Neoplasms
5
Advanced Solid Tumors
5
Neoplasms
4
Colorectal Cancer Metastatic
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Gallbladder Neoplasms
3
Cholangiocarcinoma
3
Carcinoma
3
Adenocarcinoma
3
Neutropenia
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Bile Duct Neoplasms
2
Advanced Solid Tumors (Excluding Breast Cancer)
2
Advanced Colorectal Cancer
2
Adenocarcinoma Of Esophagus
2
mCRC
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor Cancer
1
Solid Tumor
1
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anal Cancer Metastatic
×
trifluridine tipiracil drug combination
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled